Live
Activity: 12/02/2023
Activity
Launch Date: 06/24/2024
Activity
Expiration Date: 06/24/2027
Overview:
New legislation has been introduced in many
areas of the country that affects access to gender affirming care, reproductive
health, and telehealth / patient access. In addition, ongoing conflicts around
the globe create barriers to care for patients with epilepsy around the world.
This session will help providers to understand the effects of these concerns
and this legislation on the care of patients with epilepsy, so that providers
will be better prepared to address their effects on epilepsy patients.
The Hot Topics symposium focuses on current
issues and their impact on the care of patients with epilepsy. This year, the
symposium will focus on how new legislation that affects reproductive health
care, access to care, and gender-affirming care can potentially affect patients
with epilepsy. The symposium will also address the effects of wars and
conflicts on epilepsy care around the world.
Learning Objectives:
Following participation in this activity,
participants will be able to:
- Describe ways that antiseizure medications can interact with gender-affirming medical care
- Identify unique concerns faced by LGBTQIA+ patients with epilepsy
- Describe strategies to ensure that epilepsy patients in conflict zones and war-affected regions continue to receive appropriate medical treatment
- Identify and describe strategies to improve access to healthcare for patients with epilepsy
- Identify ways that antiseizure medications can potentially affect reproductive health care in women with epilepsy, and how recent policy changes may affect reproductive health care
Chairs:
Suzette LaRoche, MD, FAES;
and Sarah Schmitt, MD, FAES
Program:
Introduction | Suzette LaRoche, MD, FAES|
Epilepsy in Conflict Zones and War Affected
Regions | Olga Taraschenko, MD, PhD
Epilepsy Care in the LGBTQIA+ Population: Unique
Challenges | Emily Johnson, MD
Access to Epilepsy Care in the Post Pandemic Era
| Jonathan Edwards, MD, MBA
Navigating Reproductive Health Care in a
Changing Political Landscape | Caryn Dutton, MD
Panel Discussion | All faculty, plus Naymee
Velez-Ruiz, MD and Hind Kettani, MD
Career Stage:
Early Career (typically 0-5 years from
completion of training)
Mid-Career (typically 6-15 years from completion
of training)
Senior (typically >15 years of training)
Demographics:
Clinical, First-time Attendees, Research, Young
Professionals
Target Audience:
Advanced Practice Providers (APPs), Advocates,
Behavioral Health Providers, Clinicians, Community Health Workers,
Fellows/Trainees, Nurses, Pharmacists, Scientists/Researchers, Social Workers,
Technicians
Education Credit:
2.5 CME
Session Content Includes:
Diversity, Equity, and Inclusion (DEI)
FACULTY/PLANNER DISCLOSURES
It is the policy of the AES to make disclosures of
financial relationships of faculty, planners and staff involved in the
development of educational content transparent to learners. All faculty
participating in continuing medical education activities are expected to
disclose to the program audience (1) any real or apparent conflict(s) of
interest related to the content of their presentation and (2) discussions of
unlabeled or unapproved uses of drugs or medical devices. AES carefully reviews
reported conflicts of interest (COI) and resolves those conflicts by having an
independent reviewer from the CME Review Committee validate the content of all
presentations for fair balance, scientific objectivity, and the absence of
commercial bias. The American Epilepsy Society adheres to the ACCME’s Essential
Areas and Elements regarding industry support of continuing medical education;
disclosure by faculty of commercial relationships, if any, and discussions of
unlabeled or unapproved uses will be made.
Planning
Committee, Faculty, Reviewers’ Disclosures of Financial Relationships
In accordance with the ACCME Standards for
Integrity and Independence in Accredited Continuing Education, the AES requires
that any person who is in a position to control content of a CME activity must
disclose all relevant financial relationships that they have with an ineligible
company. Unless otherwise indicated (*), none of the planners or faculty of
this activity have any financial relationships to disclose. All relevant
financial relationships with ineligible companies have been mitigated. The following
individuals contributed to this activity’s content.
CME Reviewer
Shahram Izadyar, MD,
FAES
Resolution of Conflicts of Interest
It is the policy of the American Epilepsy Society
to ensure balance, independence, objectivity and scientific rigor. All persons
involved in the selection, development and presentation of content are required
to disclose any real or apparent conflicts of interest. In accordance with the
ACCME Standards of Integrity and Independence in Accredited Continuing
Education, the AES implemented the mechanisms of prospective peer review of
this CME activity, to identify and resolve any conflicts. Additionally, the content
of this activity is based on the best available evidence.
Accreditation
The American Epilepsy Society is accredited by the
Accreditation Council for Continuing Medical Education to provide continuing
medical education for physicians.
For more information regarding contact hours,
please call American Epilepsy Society 312.883.3800.
Credit
Designation
The American Epilepsy Society designates this live
activity for a maximum of 2.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with
the extent of their participation in the activity.
CME and CE Certificates
To receive credit for your participation in this
activity, please complete the evaluation survey provided at the conclusion of
the activity.
Unapproved
Use Disclosure
The American Epilepsy Society requires CME authors
to disclose to learners when products or procedures being discussed are
off-label, unlabeled, experimental, and/or investigational (not FDA approved);
and any limitations on the information that is presented, such as data that are
preliminary or that represent ongoing research, interim analyses, and/or
unsupported opinion. This information is intended solely for continuing medical
education and is not intended to promote off-label use of these medications. If
you have questions, contact the medical affairs department of the manufacturer
for the most recent prescribing information. Information about pharmaceutical
agents/devices that is outside of U.S. Food and Drug Administration approved
labeling may be contained in this activity.
Disclaimer
This CME activity is for educational purposes only
and does not constitute the opinion or endorsement of, or promotion by, the
American Epilepsy Society. Reasonable efforts have been taken to present
educational subject matter in a balanced, unbiased fashion, and in compliance
with regulatory requirements. However, each activity participant must always
use his or her own personal and professional judgment when considering further
application of this information, particularly as it may relate to patient diagnostic
or treatment decisions including, without limitation, FDA-approved uses and any
off-label, investigational and/or experimental uses.